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Abstract The roseoloviruses, human herpesvirus (HHV)-6A,
HHV-6B, and HHV-7, can cause severe encephalitis or enceph-
alopathy. In immunocompetent children, primary HHV-6B
infection is occasionally accompanied by diverse clinical forms
of encephalitis. Roseolovirus coinfections with heterologous
viruses and delayed primary HHV-7 infection in immunocom-
petent adults result in very severe neurological and generalized
symptoms. Recovery from neurological sequelae is slow and
sometimes incomplete. In immunocompromised patients with
underlying hematological malignancies and transplantation,
frequent single or simultaneous reactivation of roseoloviruses
elicit severe, lethal organ dysfunctions, including damages in
the limbic system, brain stem, and hippocampus. Most cases
have been due to HHV-6B with HHV-6A accounting for
2–3%. The most severe manifestation of HHV-6B reactivation
is post-transplantation limbic encephalitis. Seizures, cognitive
problems, and abnormal EEG are common. Major risk factors
for HHV-6B-associated encephalitis include unrelated cord
blood cell transplantation and repeated hematopoietic stem cell
transplantation. Rare genetic disorders, male gender, certain
HLA constellation, and immune tolerance to replicating HHV-
6 in persons carrying chromosomally integrated HHV-6 might
also predispose an individual to roseolovirus-associated brain
damage. At this time, little is known about the risk factors for
HHV-7-associated encephalitis. Intrathecal glial cell destruction
due to virus replication, overexpression of proinflammatory cy-
tokines, and viral mimicry of chemokines all contribute to brain
dysfunction. High virus load in the cerebrospinal fluid, hippo-
campal astrogliosis, and viral protein expression in HHV-6B-
associated cases and multiple microscopic neuronal degenera-
tion in HHV-7-associated cases are typical laboratory findings.
Early empirical therapy with ganciclovir or foscarnet might save
the life of a patient with roseolovirus-associated encephalitis.
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Introduction
Viral encephalitis is a medical emergency. It is an aseptic
inflammatory process of the brain parenchyma associated
with clinical evidence of brain dysfunction, significant mor-
bidity, and mortality (Michael and Solomon 2012). It has two
forms: epidemic and sporadic. The characteristics of brain
involvement and prognosis of the disease depend on the
pathogen and the physical state of the host (Kawamura et al.
2013; de Ory et al. 2013; Zerr et al. 2011). Its outcome
depends on rapid clinical and microbial diagnosis, and the
prompt administration of adequate antiviral therapy (Michael
and Solomon 2012). Viral encephalitis frequently involves the
meninges, causing meningoencephalitis, or the spinal cord,
eliciting encephalomyelitis. Encephalopathy is mediated via
metabolic processes and can be caused by systemic infection
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that spares the brain (Chapenko et al. 2016; Miranda et al.
2011; Raspall-Chaure et al. 2013; Steiner et al. 2010).
Human herpesvirus 6 species A and B (HHV-6A and
HHV-6B; Ablashi et al. 1991; Dagna et al. 2013; Salahuddin
et al. 2007) and HHV-7 (Frenkel et al. 1990) have been
regarded as lymphotropic and neurotropic viruses (Ablashi
et al. 2000; Chapenko et al. 2016; Savolainen et al. 2005). In
Africa, 86–100% of infants acquire HHV-6Awithout specific
symptoms (Bates et al. 2009; Hall et al. 2006; Kasolo et al.
1997; Sjahril et al. 2009), but a recent study has shown that in
biobanked sera specimens from hospitalized Zambian chil-
dren between 3 weeks and 2 years of age who were admitted
with febrile illness, HHV-6B DNAemia was predominant
over HHV-6A (20.5 % versus 0.3 %; Tembo et al. 2015).
Primary infant infections in Europe, USA, and Japan are
predominantly HHV-6B (97–100%) and result in a self-
limited fever, with 10–24% of children also developing the
associated skin rash, exanthem subitum (roseola infantum;
Hall et al. 1994, 2006; Zerr et al. 2005). Both HHV-6A and
HHV-6B are implicated as etiological agents or cofactors for a
diverse array of pathological conditions in the central nervous
system (CNS), such as different clinical forms of encephalitis,
encephalopathy, epilepsy, febrile convulsions, meningitis,
multiple sclerosis (Alvarez-Lafuente et al. 2007; Crawford
et al. 2007; Ongradi et al. 1999c; Yao et al. 2010a), chronic
fatigue syndrome (CFS; Ablashi et al. 2000; Komaroff 2006)
and tumors (Crawford et al. 2009; Kawabe et al. 2010). All
three virus species establish a life-long latency in the immune
system and influence the function of immune cells via aber-
rant cytokine and chemokine patterns or by producing their
own chemokines and chemokine receptors (Clark et al. 2013;
Crawford et al. 2009; Dagna et al. 2013; Yoshikawa et al.
2011). HHV-6A and HHV-6B persist in the brain (Luppi
et al. 1995; Yoshikawa et al. 2000) and can induce neuroin-
flammation via interleukin (IL) production (Yao et al. 2010b).
Single, simultaneous, or consecutive reactivation also elicits
debilitating conditions with involving CNS diseases (Holden
and Vas 2007; Lautenschläger and Razonable 2012). HHV-6
species are able to transactivate heterologous viruses, especially
HIV (Corti et al. 2011; Ongrádi et al. 2011) and human
endogenous retroviruses (HERVs; Tai et al. 2009; Turcanova
et al. 2009), which cause brain damage. Reactivation of HHV-6
in patients with AIDS can result in encephalitis or meningoen-
cephalitis (Knox et al. 1995). The presence of HHV-6DNA and
proteins in demyelinated brain areas suggests that they play an
active role in neurological complications (Knox and Carrigan
1995; Knox et al. 1995; Saito et al. 1995).
HHV-6A and HHV-6B, but not HHV-7, can integrate into
the telomeric region of human chromosomes (Arbuckle et al.
2010; Luppi et al. 1995; Montoya et al. 2012; Morissette and
Flamand 2010; Lautenschläger and Razonable 2012; Pantry
et al. 2013). In approximately 0.2–0.35 % of the population in
Japan and Canada (Gravel et al. 2013b; Tanaka-Taya et al.
2004) and 0.8–0.85 % of the population in the USA and UK
(Hall et al. 2010; Leong et al. 2007; Ward et al. 2006), HHV-6
is transmitted vertically by standard Mendelian inheritance
(Morissette and Flamand 2010). Cells with chromosomally
integrated HHV-6 (ciHHV-6) are transmitted to cell and organ
transplant recipients with unknown consequences. CiHHV-6
has been shown to activate in vitro (Arbuckle et al. 2010) and
in vivo (Endo et al. 2014), and affected individuals can pro-
duce infectious virions from their own integrated strains that
are activated under conditions of extreme immunosuppression
(Endo et al. 2014). It would therefore be helpful for ciIHHV-6
status to be identified perinatally (Hall et al. 2010). Bans on
donations of organs, blood, germ cells, and hematopoietic
stem cells from these individuals have been suggested
(Flamand 2014; Pellett et al. 2012; Wittekindt et al. 2009).
Women with ciHHV-6 can pass their activated HHV-6 to the
fetus transplacentally (Hall et al. 2010) and the strains of their
congenitally infected fetuses are identical to their integrated
strain (Gravel et al. 2013a). CiHHV-6 patients may have tol-
erance and an inability to control exogenous HHV-6A or B
infections (Pantry et al. 2013; Tanaka-Taya et al. 2004), and
some of them suffer from neurological symptoms (Lee et al.
2011; Pantry et al. 2013) for several years with remittences
and relapses (Montoya et al. 2012). In a recent series of 366
adult allogeneic HSCT recipients, 4 % of HHV-6 positive
individuals were ciHHV-6 carriers (Quintela et al. 2016).
HHV-7 is ubiquitous worldwide. By the age of 4 years,
approximately 70 % of children have contracted the infection
(Adams and Carstens 2012; Ongradi et al. 1999b), but a recent
study in Sub-Saharan Africa found that most primary infections
appear to occur in young neonates, and subsequently, a very
stable prevalence of around 20 % among children >12 months
of age was shown by DNAemia. The same study found double
infections involving CMV,HHV-6B, or HHV-7 in 3.0–8.9% of
cases, while triple infections involving CMV, HHV-6B, and
HHV-7 occured in 2 and 0 % of coinfections involved HHV-
6A (Tembo et al. 2015). In children, HHV-7 might elicit exan-
them subitum; while in seronegative adults, it might induce
pityriasis rosea (Drago et al. 1997; Vág et al. 2004). HHV-7
also invades the brain (Chapenko et al. 2016; Martikainen et al.
2013). Primary infection occasionally induces febrile convul-
sions or encephalitis and primary infection was found in 8–9 %
of children suspected of encephalitis in the UK (Ward 2005).
Reactivation of HHV-7 in immunocompromised conditions
elicits a wide array of severe CNS diseases. HHV-7 can
transactivate HHV-6B and human parvovirus B19 (PV-B19;
Ongrádi et al. 2000). Simultaneous HHV-6B, HHV-7, and
PV-B19 infection was demonstrated in some patients with
myalgic encephalitis (ME/CFS; Chapenko et al. 2012a).
However, HHV-7 does not activate HIV-1 (Ongrádi et al.
2011) or HERV-K18 (Oakes et al. 2013). HHV-7 has profound
immunomodulating activity through altering the cytokine pro-
file and encoding chemokine receptors (Atedzoé et al. 1999).
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HHV-6A and HHV-6B ( Ablashi et al. 2014; Adams and
Carstens 2012) are discussed separately; the general term
HHV-6 is reserved for studies where the distinction was not
made (Lautenschläger and Razonable 2012). Roseoloviruses
might induce both encephalitis and encephalopathy
(Chapenko et al. 2016). These clinical entities are discussed
individually when possible. The majority of related publica-
tions are case studies or small cohorts up to one or two dozen
individuals (Al-Zubeidi et al. 2014; Hill et al. 2012). Unusual
clinical presentations and descriptions as well as inconclusive
laboratory results are common because of the wide range of
biomarkers that have been studied (Fay et al. 2015;
Maramattom 2015; Ward et al. 2002; Yamamoto et al. 2014;
Zerr et al. 2011). These difficulties hinder unambigous gener-
alization concerning disease course and roseolovirus etiology
(Esposito et al. 2015; Hill et al. 2015a, b).
Clinical presentation of roseolovirus-associated
encephalitis
An acute encephalitis might occur either after a primary infec-
tion in an immunocompetent individual or after becoming
immunocompromised due to an underlying condition. Over
the past 10 years, viral encephalitis has gained recognition as
an important complication in cell and organ transplantation
settings (de Ory et al. 2013; Ibrahim et al. 2005; Imataki and
Uemura 2015; Ljungman 2002; Steiner et al. 2010; Michael
and Solomon, 2012; Scheurer et al. 2013).
Encephalitis in immunocompetent individuals
Encephalitis is suspected in small children when an altered
level of consciousness, significant change in personality, cog-
nitive dysfunction, or focal neurological symptoms persist for
≥24 h, and other causes are excluded. The disease is accom-
panied by headache, nausea, temperature of ≥38 °C, and spe-
cific laboratory results (Ibrahim et al. 2005). Long before the
etiology of ES was established, its association with occasional
convulsions and encephalopathy had been observed
(Berenberg et al. 1949). Meningoencephalitis associated with
HHV-6-related exanthem subitum was reported later (Ishiguro
et al. 1990). Since the first published fatal case (Asano et al.
1992), primary HHV-6B infection with or without manifesta-
tion of exanthem subitum but accompanied by febrile sei-
zures, acute encephalitis, meningitis, or demyelinating disease
in children and adults have been described (de Ory et al. 2013;
Yoshikawa et al. 2009). Febrile seizures occur in 20–43 % of
children from 6 months to 5 years of age (Epstein et al. 2012;
Laina et al. 2010). The first episode is frequently attributed to
primary HHV-6B infection, whereas further episodes are not
(Yavarian et al. 2014). Eight to 20 % of children with primary
HHV-6 infection demonstrate febrile seizures as a main
manifestation (Asano et al. 1994). There is a potential link
between febrile seizures, temporal lobe epilepsy (TLE), and
hippocampal sclerosis (Li et al. 2014). HHV-6B encephalitis
has various types of clinical courses, including acute necrotiz-
ing encephalopathy (ANE), hemorrhagic shock and encepha-
lopathy syndrome (HSES), and acute encephalopathy with
biphasic seizures and late reduced diffusion (AESD;
Hoshino et al. 2012; Kawamura et al. 2013, 2014). In 40 %
of cases, low HHV-6 load has been detected in the CSF (Yao
et al. 2009). Convulsions are frequently atypical and can
sometimes lead to status epilepticus (Al-Zubeidi et al. 2014;
Asano et al. 1992; Iwasaki et al. 2014; Shahani 2014). Of 169
infants with status epilepticus, 32 % had active HHV-6B and
7 % had HHV-7 infection. Of those, with active infections, a
primary infection was found in 70 % of HHV-6B and 67 % of
HHV-7 status epilepticus cases with the rest identified as re-
activation (Epstein et al. 2012). The exact fatality rate of
HHV-6B-associated encephalitis at the time of primary infec-
tion remains unclear. Disabling sequelae (e.g., visual impair-
ment, speech disturbance, persistent hemiplegia, quadriplegia,
and mental retardation) are frequent in children after an HHV-
6B encephalitis or meningoencephalitis course (Bozzola et al.
2012; Kawamura et al. 2014; Raspall-Chaure et al. 2013). A
survey estimated 60 exanthem subitum-associated encephali-
tis cases with two fatal outcomes annually in Japan and almost
half of those children experience severe neurological sequelae
(Yoshikawa et al. 2009).
In apparently normal children, reports draw attention to
the association between rare genetic disorders and poor
neurologic outcome following HHV-6B infection. Two
boys 10 and 12 months old, presented with HHV-6B en-
cephalitis, and ultimately died due to Alpers–Huttenlocher
syndrome. They were treated with ganciclovir resulted in
declining viral load without neurological improvement.
Both children were heterozygotes for mutations in the mi-
tochondrial polymerase gamma gene (POLG). This pheno-
type could be unmasked and/or exacerbated by HHV-6B
infection, potentially contributing to clinical deterioration.
Mutations in POLG have recently been identified in a num-
ber of neurological syndromes including encephalopathy
and seizures (Al-Zubeidi et al. 2014). The thermolabile
phenotype of another mitochondrial enzyme, carnitine
palmitoyl-transferase 2, has also been implicated in acute
HHV-6B-associated encephalopathy. This enzyme is found
in Japanese people and is involved in the production of
ATP. During high fever, the enzyme is inactivated leading
to an energy crisis (Kobayashi et al. 2013).
Encephalitis in immunocompetent children due to primary
HHV-7 infection is rare. An acute HHV-7 infection in the CSF
might be accompanied by severe neurological and generalized
symptoms, including encephalitis, meningoencephalitis, en-
cephalopathy, facial palsy, vestibular neuritis, febrile or focal
seizures, severe headache, somnolence, fatigue, nausea,
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vomiting, fever up to 39.8 °C, photosensitivity, lethargy, im-
paired orientation, difficulties in walking, tendency to fall to
one side (straddle gait), tiredness, sudden onset of dizziness,
and comatous state (Chan et al. 2002; Ward 2005; Epstein
et al. 2012; Pohl-Koppe et al. 2001; Venancio et al. 2014).
Delayed primary HHV-7 infection in older children and ado-
lescents can cause more serious neurological complications.
In 2,972 hospitalized pediatric patients (mean age 10.1 years),
HHV-7 DNA was found in the CSF of 57 concomitant with
meningitis, encephalitis, or severe CNS disorders (acute dis-
seminated encephalitis/ADEM/optic neuritis, transverse mye-
litis, cranial nerve VI palsy, Guillan–Barré syndrome).
Learning disabilities persisted even after clinical recovery
(Schwartz et al. 2014). In an 11-year-old male with encepha-
litis symptoms, MRI demonstrated FLAIR abnormalities
supratentorially and infratentorially, most prominently involv-
ing the brainstem, with diffuse post-contrast enhancement in
the pons and a ring-enhancing lesion in the cerebellum subse-
quently evolving scattered microhemorrhages, necrosis of the
pontine lesions. CSF was notable for the presence of HHV-7,
leukocytosis (lymphocyte predominance), red cells, glucose,
and protein. Sequelae (one-sided weakness, ataxia, and
dysarthric speech) gradually normalized (Fay et al. 2015). In
adults, primary HHV-7 infection-associated encephalitis is
rare but is concomitant with severe generalized symptoms,
such as urinary retention, respiratory failure, and flaccid pa-
ralysis of the limbs progressing to quadriplegia (Miranda et al.
2011; Schwartz et al. 2014; Ward 2005; Ward et al. 2005).
Recently, the combination of a genetic disorder (anti-N-meth-
yl-D-aspartate receptor dysfunction) and HHV-7 DNA posi-
tivity in the CSF has been described in a 9-year-old boy with
typical neurological symptoms (Venancio et al. 2014).
No encephalitis cases have been published after a simulta-
neous primary infection with HHV-6 and HHV-7. In children
presenting with febrile status epilepticus, primary HHV-7 in-
fection and consequent HHV-6B reactivation were found
(Epstein et al. 2012). Coincident HHV-7 and cytomegalovirus
(CMV) infection-associated encephaloradiculomyelitis has
been described (Ginanneschi et al. 2007). In a cohort of 22
cases of herpes simplex virus (HSV)-induced encephalitis,
three had both HSV and HHV-6 in their CSF, two of whom
died (Ward 2005).
Herpesviruses and other latently carried viruses frequently
reactivate in immunocompetent individuals with or without
clinical symptoms. In a 64-year-old man, detection of HHV-
6 in the CSF was associated with encephalo-myocarditis
(Maramattom 2015). Occasionally, double infection by
HSV-1 and CMV or HSV-1 and HHV-6 was detected in the
CSF of encephalitis patients by polymerase chain reaction
(PCR; Ibrahim et al. 2005). Significantly higher detecion fre-
quency of single HHV-6B and concurrent HHV-6B+HHV-7
DNAwas found in pia mater meninges, the frontal lobe, and
olfac tory nerve in individuals wi th unspeci f ied
encephalopathy (UEP) compared to the control group
(Chapenko et al. 2016). Additionally, HHV-7 may induce in-
direct effects in the body which act as a risk factor for CMV
reactivation and diseases (Ljungman 2002). In adults with
ME/CFS, frequent reactivation of HHV-7, PV-B19, HHV-
6B+HHV-7, HHV-7+PV-B19, and HHV-6B+HHV-7+PV-
B19 was concomitant with impaired memory or concentra-
tion, unrefreshing sleep, new type of headache, and rheumatic
symptoms. High viral load in peripheral blood lymphocytes
was accompanied by high plasma levels of proinflammatory
tumor necrosis factor (TNF)-alpha, IL-6, and undetectable
levels of anti-inflammatory IL-4 (Chapenko et al. 2012a). In
patients with influenza virus-associated encephalopathy, no
association with primary or reactivated HHV-6 or HHV-7 in-
fection was found (Kawada et al. 2003).
Encephalitis following roseolovirus reactivation
in immunocompromised patients
Despite frequent (40–60 % of cases; Deconinck et al. 2013;
Zerr et al. 2011) HHV-6 reactivation after stem cell (SCT),
bone marrow (BMT), and solid organ (SOT) transplantation,
a small percentage of patients develop HHV-6-associated en-
cephalitis (Hill et al. 2012; Ljungman 2002; Ogata et al. 2010;
de Oliveira et al. 2015; Sakai et al. 2011; Zerr et al. 2011).
Viremia is common 2–6 weeks after transplantation
(Yoshikawa et al. 2002b; Zerr 2006; Zerr et al. 2011), but early
viral reactivation in the brain might cause encephalitis
(Drobyski et al. 1994; Hirabayashi et al. 2013; Ishiyama
et al. 2011; Ward 2005). Onset of encephalitis was recorded
at a median of 15 (Zerr et al. 2011), 18 (Sakai et al. 2011), or
24 days post-transplantation (Zerr 2006), but it might develop
somewhat earlier (Hill et al. 2015a, b) or several weeks later
(Drobyski et al. 1994). Patients generally were young—medi-
an age, 35 years; range 6–54 years (Zerr 2006) and median
40.5 years elsewhere (Sakai et al. 2011). Occasionally, elder
recipients might suffer from HHV-6 encephalitis (Hill et al.
2015a, b) and status epilepticus (Shahani 2014). CNS symp-
toms can be partially different from those seen in primary
HHV-6 infection-associated encephalitis and often include de-
pressed consciousness, confusion, disorientation, insomnia,
memory problems (especially short-term memory), clinical
and electrographic seizures, and imaging abnormalities
(Drobyski et al. 1994; Hirabayashi et al. 2013; Singh and
Paterson 2000; Zerr 2006; Zerr et al. 2011). Post-
transplantation acute limbic encephalitis (HHV-6-PALE) with
high mortality is the most typical and severe manifestation,
especially after HSCT (Howell et al. 2012; Kawamura et al.
2013, 2012; Ogata et al. 2010; Raspall-Chaure et al. 2013).
Small amounts of viral DNA may signify an active infection
(Yao et al. 2010a). Sequelae due to hippocampal sclerosis and
dysmaturation of the temporal lobe after HHV-6-PALE might
develop as epilepsy or loss of attained language and social
4 J. Neurovirol. (2017) 23:1–19
skills (Howell et al. 2012). Both direct effects of chronic or
reactivated HHV-6 infection and autoimmune mechanisms
are suspected (Raspall-Chaure et al. 2013). In one case, pos-
terior reversible encephalopathy syndrome (PRES) has been
associated with HHV-6B infection (Kawamura et al. 2013,
2012), and in another case, PRES was elicited by combined
chemotherapy consisting of drugs known to activate HHV-6,
although its presence was not tested (Tsukamoto et al. 2012).
Host defense systems that are suppressed due to reasons other
than transplantation might also predispose to HHV-6 reactiva-
tion and encephalitis. A 2-month-old boy with X-linked se-
vere combined immunodeficiency (X-SCID) and ciHHV-6A
was hospitalized with hemophagocytic syndrome and a high
HHV-6A load in his blood. After HSCT and antiviral treat-
ment he became asymptomatic. Although he avoided enceph-
alitis or encephalopathy, similar case studies might describe
CNS involvement (Endo et al. 2014).
HHV-7 reactivation from neurolatency has been associated
with encephalitis in BMT patients (Ljungman 2002). HHV-7
reactivation has not been observed at a constant time post-
SCT (Inazawa et al. 2015; Savolainen et al. 2005). After re-
ceiving combined immunosuppressive chemotherapy, irradia-
tion, and HSCT for acute lymphoblastic leukemia (ALL), a
small girl developed visual and hearing impairment, bulbar
dysfunction, confusion, cardiorespiratory insufficency, and
died in spite of ganciclovir therapy. Her CSF sample was
positive contrary to other leukemic children who did not have
encephalitis or HHV-7 in the CSF. This suggests an active role
for HHV-7 in CNS damage. These authors estimated that
HHV-7 accounts for 1.3–5.7 % of pediatric encephalitis cases
(Chan et al. 2002), while others found an incidence of 2 (de
Oliveira et al. 2015) or 8 % (Inazawa et al. 2015) after alloge-
neic HSCT. In addition, HHV-7 reactivation-associated en-
cephalitis has followed initial first course of encephalitis in-
duced by HHV-6 after HSCT. Several weeks of renewed fos-
carnet therapy resulted in neurological improvement (Holden
and Vas 2007). HHV-7 reactivation after transplantation may
also lead to CMV reactivation and CMV disease (Chan et al.
1997; Chapenko et al. 2012b; Kidd et al. 2000). HHV-7 viremia
was found mostly (94 %) before CMV reactivation, which sug-
gests a possible interaction between these Betaherpesviruses
(Tomaszewska et al. 2014). HHV-7 may worsen immunodefi-
ciency through aggravating cytokine dysfunction (Ginanneschi
et al. 2007). Its ability to induce high levels of IL-10 might
contribute to CNS disorders (Ongrádi et al. 1999a).
Pathology and pathogenesis
HHV-6A and HHV-6B infect different cells (Donati et al.
2005; Lusso et al. 1991, 1995) and that phenomenon might
determine the clinical findings in the CNS (Yao et al. 2010a).
Species A gains access to the CNS by crossing the blood-brain
barrier (BBB) through the olfactory ensheating cells (OEC).
These cells support HHV-6A replication in vitro and produce
proinflammatory cytokines, such as IL-6, chemokines CCC-1,
and CCL5 (regulated upon activation normal T cell expressed
and secreted, RANTES). As with other viruses that utilize the
olfactory route, the presence of HHV-6 in limbic tissues can
lead to limbic encephalitis (Harberts et al. 2011). Recently,
HHV-6B has been found in the endotheliocytes and oligoden-
drocytes of the olfactory tract and the frontal and temporal
lobes. High HHV-6B load in the pia mater suggests that
HHV-6 may also use this loose vascular coat as a pathway
to enter CNS (Chapenko et al. 2016). HHV-6A replicates in
neuronal stem cells (De Filippis et al. 2006), progenitor-
derived astrocytes (Donati et al. 2005), and oligodendrocyte
progenitor cells (Ahlqvist et al. 2005). HHV-6B infection in
the astrocytic cell line U251 leads to abortive infection, where-
as HHV-6A infection leads to replication (Donati et al. 2005;
Yoshikawa et al. 2002a). Infection of oligodendrocytes may
be associated with multiple sclerosis, whereas productive in-
fection of astrocytes may be more common in other CNS
disorders such as mesial temporal lobe epilepsy (MTLE) and
encephalitis (Donati et al. 2003; Drobyski et al. 1994). HHV-6
displays tropism for hippocampal astrocytes (Ogata et al.
2010; Zerr, 2006) and causes neuronal loss in the infected
areas (Howell et al. 2012; Yao et al. 2010a) after HSCT
(Sakai et al. 2011) or BMT (Drobyski et al. 1994). In hippo-
campal specimens obtained from patients with TLE, decade-
long persistence of HHV-6B was proven (Esposito et al.
2015). HHV-6A productively infects glial cells, while HHV-
6B causes their persistent infection (refs in Yao et al. 2010a).
In pediatric gliomas that were HHV-6 positive, 72 % were
positive for HHV-6A (Crawford et al. 2009). Species specific
immune modulation (Dagna et al. 2013; Ongrádi et al. 2006;
e.g., differences in chemokine expression) contributes to the
predominance of HHV-6B in neuroinflammatory disease
(Buckner et al. 2011). In HHV-6B-associated status
epilepticus and subsequent TLE (Epstein et al. 2012), there
is evidence for a role for CCL2-CCR2 signaling (van Gassen
et al. 2008) through molecular mimicry. The N-terminal (NT)
peptide fragment of CCL2 (formerly known as monocyte che-
motactic protein /MCP/-1) is expressed by HHV-6B U83N as
the U83B-NT peptide (French et al. 1999) in latently infected
cells and in persons carrying ciHHV-6. Upon binding CCR2,
it enhances chemotaxis of CCR2-bearing monocytes. In many
infections, CCL2 mediates monocyte movement across the
BBB and neuroinflammatory diseases (Buckner et al. 2011).
HHV-6A U83A-NT is specific for other chemokine receptors
and consequently does not elicit chemotaxis.
Cytokine patterns in the CSF were found to be different in
encephalitis cases occurring after primary infections and reac-
tivation in transplant recipients (Ichiyama et al. 2009;
Kawamura et al. 2011). In small children presenting fever
but no sign of CNS involvement at time of HHV-6B
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seroconversion, elevated serum IFN-gamma, IL-2, IL-4, and
MCP-1 levels in the acute phase and a higher IL-5 level in the
convalescent period were shown (Yoshikawa et al. 2011).
Infants with primary HHV-6 infection-associated encephalitis
show higher serum and CSF levels of IL-6. SCT recipients
have a tendency to display hypercytokinemia. Among these
patients, elevated levels of IL-6 have been detected before
HHV-6 reactivation and progression towards encephalopathy
(Ogata et al. 2010). A high CSF level of IL-8 relative to serum
levels (Kawabe et al. 2010) and elevated levels of IL-10, IFN-
gamma, IL-8, tissue regenerating matrix metalloproteinase
(MMP)-9, and tissue inhibitor of matrix metalloproteinase
(TIMP)-1 were found in encephalitis patients but not in
healthy individuals (Ichiyama et al. 2007; Kawabe et al.
2010; Ogata et al. 2010). Variable serum patterns might be a
characteristic of different courses of HHV-6B encephalitis;
indeed, the cytokine storm in HSES or ANE has stood in
contrast to more modest cytokine changes in AESD
(Kawamura et al. 2013). In AESD, significantly elevated se-
rum levels of IL-10 and IL-8 were found, while serum IL-
1beta and MCP-1 concentrations were lower than in controls.
The patients’ levels of IL-10, RANTES, and monokine in-
duced by IFN-gamma (MIG) were significantly higher in se-
rum than in CSF; IL-6, IL-8, and MCP-1, however, were
significantly higher in CSF than in the serum. Serum IL-10
was significantly higher in AESD patients with sequelae than
in those without sequelae, and therefore, high IL-10 might
signify a poor prognosis. Elevation of MCP-1 levels in CSF
may be induced by neurons, astrocytes, or microglia and not
leaked from systemic circulation. Higher IL-6 and IL-10
levels are frequently measured in several neurological disor-
ders, including encephalitis (Asano et al. 2010; Ichiyama et al.
2009). Elevated levels of these cytokines may play an impor-
tant role in the pathogenesis of HHV-6B-associated AESD via
recruitment of monocytes/macrophages and neutrophils or via
activation of glial cells (Kawamura et al. 2013). In vitro reac-
tivation of HHV-6B infection in an astrocytoma cell line re-
sulted in the overproduction of IL-6 and IL-1beta (Yoshikawa
et al. 2002a). High CSF levels of IL-1beta and IL-8 triggers
vasogenic edema in the brain (Kawamura et al. 2013, 2012).
High plasma IL-6 levels were also found in a patient with
ciHHV-6 (Montoya et al. 2012). Elevated levels of IL-6, sol-
uble TNF receptor (sTNFR)-1, and CSF IL-1 predict neuro-
logical sequelae (Ichiyama et al. 2009; Montoya et al. 2012).
These alterations are similar to those found in acute encepha-
litis induced by other viruses and suggest the existence of a
pathway that is partially conserved across species (Hoshino
et al. 2012; Kawada et al. 2003; Singh and Paterson 2000).
In male adults with drug-resistant epilepsy, HHV-7 proteins
were detected in the astrocytes and oligodendrocytes of hippo-
campal sclerosis samples. Glial scar, arachnoid cyst, focal cor-
tical dysplasia, and vascular malformation are associated with
HHV-7 infection. Beside normal TNF-alpha, IL-1, and IL-6
levels, tumor growth factor (TGF)-beta upregulation found in
degenerating neurons of the pyramidal cell layer suggests a
possible association with persistent glial-tropic HHV-7 infec-
tion and chronic neuroinflammatory conditions via glio-
neuronal communication (Li et al. 2014). Simultaneous detec-
tion of HHV-6+HHV-7 DNA in the frontal lobe, but not in the
temporal lobe of patients with UEP, suggests that their potential
interaction can affect the brain through cytokine mediated
immunomodulation (Chapenko et al. 2016).
Research on pathomechanism has long been hindered due to
a lack of appropriate animal models (Reynaud and Horvat
2013). Upon HHV-6A and HHV-6B infection of murine prima-
ry oligodendrocyte precursors, transcription of viral genes was
detected, but viral replication did not occur (Mock et al. 2006).
Several monkey species carry detectable antibodies due to nat-
ural infection. An HHV-6B homolog (PanHV-6) was isolated
from chimpanzees (Pan triglodytes); however, infection remains
asymptomatic (Lacoste et al. 2005). In pig-tailed macaques
(Macaca nemestrina), experimental HHV-6A infection acceler-
ated simian immunodeficiency virus (SIV) infection and the
progression of pathological conditions, but no neurological
symptoms have been described (Lusso et al. 2007).
Intravenous HHV-6A infection in common marmosets
(Callithrix jacchus) resulted in neurological symptoms includ-
ing motor weakness and sensory abnormalities, while infection
with HHV-6B remained asymptomatic. HHV-6A and HHV-6B
DNA could be occasionally detected in the brain of animals and
MRI revealed hyperintense lesions in the brain of one animal.
Intranasal HHV-6A infection rarely induced seroconversion or
manifested in disease. Neurological symptoms observed with
intravenous injection might be due to the immune response
raised against HHV-6 rather than to the direct effect of HHV-6
(Leibovitch et al. 2013). Mice with SCID and humanized mice
show promise as animal models for learning about HHV-6 path-
ogenesis (Tanner et al. 2013). In CD46 transgenic animals,
HHV-6A, but not HHV-6B, established long-term (9 months)
persistence in the brain. Neuroinflammation, such as that asso-
ciated with chemokine CCL5 (RANTES) production by glial
cells via HHV-6A binding to toll-like receptor (TLR)-9, has
been documented (Reynaud et al. 2014). Recently, novel
Betaherpesvirus DNA related to HHV-7 have been found in
the peripheral bloodmononuclear cells (PBMC) ofAfrican great
apes by PCR (Lavergne et al. 2014). On the whole, the animal
experiments seem to reflect the findings in human cases.
Epidemiology and risk factors
Risk factors for encephalitis associated with primary
infection
Roseoloviruses are ubiquitous; the etiological spectrum is not
influenced by geography. Most primary HHV-6B infection
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occurs in the second 6 months of life, while HHV-7 primary
infection occurs in the second or third year (Ongrádi et al.
1999b; Ward 2005). This temporal sequence does not apply
in children with encephalitis or seizures in which the median
age is 1 year for both. Absence of previous HHV-6 infection
predisposes to HHV-7-induced neurological morbidity due to
lack of cross-reacting antibodies (Ward 2005). The majority of
children and adults suffering from HHV-6 and HHV-7 en-
cephalitis are male (Ginanneschi et al. 2007; Kawada et al.
2003; Ongrádi et al. 2013; Pohl-Koppe et al. 2001; Schwartz
et al. 2014; Ward et al. 2002), and the highest incidence of
encephalitis (70%) occurred in winter (Yavarian et al. 2014).
Higher frequency of encephalitis cases in Japan compared to
the rest of the world might reflect genetic susceptibility
(Kobayashi et al. 2013) or more conscientious monitoring
(Yoshikawa et al. 2009). Rare genetic alterationss might pre-
dispose to neurological disorders among them HHV-6-
associated encephalopathy (Al-Zubeidi et al. 2014). There
are also risk factors associated with medical practice. For
small children with exanthem subitum, physicians might pre-
scribe unnecessary antibiotics which can have adverse effects
in the presence of HHV-6 infection. Amoxicillin (Mardivirin
et al. 2010), carbamazepine, and sodium valproate
(Mardivirin et al. 2009) have been shown to activate HHV-6
in vitro; thus, they might facilitate the development of enceph-
alopathy. Hydrocortisone is a strong enhancer of HHV-6 rep-
lication (Arbuckle et al. 2010), and prednisolone derivates
given to suppress skin rash might contribute to higher CSF
viral load (Hill et al. 2015a, b), but in children with CNS
diseases, prednisolone therapy (Kawamura et al. 2013; Pohl-
Koppe et al. 2001) helps protect the BBB (Kawamura et al.
2013; Steiner et al. 2010; Venancio et al. 2014; Yamamoto
et al. 2015).
Risk factors for encephalitis associated with virus
reactivation
Today, reactivation of roseoloviruses is almost exclusively
detected in patients with special conditions. Although HHV-
6 reactivation is relatively common among immunocompro-
mised individuals, the incidence of encephalitis among them
is low (Drobyski et al. 1994; Ogata et al. 2010; Sakai et al.
2011; Zerr 2006; Zerr et al. 2011). Reactivation may not be a
problematic event per se, suggesting that certain attributes of
the patients may be related to encephalitis or encephalopathy
(Yamamoto et al. 2014). Most cases have been due to HHV-
6B with HHV-6A accounting for only 2–3 (Sakai et al. 2011)
or 11 % (Zerr 2006). In autopsy samples from patients with
UEP, only HHV-6B was detected (Chapenko et al. 2016).
Certain normal genetic constellations in the immune system
might predispose an individual to HHV-6-associated enceph-
alopathy. In a cohort of 130 recipients with acute leukemias
and allo-HSCT HHV-6, HLA class I phenotype of recipients
was not related to HHV-6 reactivation ( = 38.1 %), while
encephalopathy was more frequent ( = 5.1 %) in patients with
HLA-B* 40.06. This allele might be related to lesser cytotoxic
T cell recognition of virus-infected cells (Yamamoto et al.
2014). Younger patients, especially children or adults in their
20s or 30s after HSCTor SCT (Hirabayashi et al. 2013; Singh
and Paterson 2000; Zerr 2006; Zerr et al. 2011), are at high
risk, as well. Underlying hematologic malignancies with more
advanced conditions, allogeneic transplants, unrelated, mis-
matched or gender mismatched donors, repeated HSCT, and
more importantly unrelated umbilical cord blood cell trans-
plantation (UCBT) have been identified as major risk factors
(de Oliveira et al. 2015; Hirabayashi et al. 2013; Ishiyama
et al. 2011; Ogata et al. 2013b; Quintela et al., 2016;
Raspall-Chaure et al. 2013; Sakai et al. 2011; Shimazu et al.
2013; Zerr et al. 2011). In a cohort of HHV-6-PALE patients,
9.9 % developed limbic encephalitis after UCTB and 0.7 %
developed the condition after adult-donor HSCT. Death from
HHV-6-PALE occurred in 50 % of affected patients undergo-
ing UCBT, while no recipients of adult-donor cells died (Hill
et al. 2012). Prevalence of HHV-6 reactivation and encepha-
litis was also significantly higher in other patient groups re-
ceiving UCBT than in patients receiving another stem cell
source (72.0 % versus 37.4 % and 8.3 % versus 0.5 %, respec-
tively; Scheurer et al. 2013). UCBT predisposes to platelet
engrafment failure (de Oliveira et al. 2015), and along with
steroid treatment and anti-thymocyte globulin use, has been
confirmed to be a risk factors for viral reactivation after allo-
geneic HSCT (Inazawa et al. 2015). Similarly, the risk of
HHV-7 transmission and reactivation in UCBT recipients is
increased. A survey of UCBT donors showed that the mean
viral load in latent cases was 1.31 × 101 copies/ml and
1.94 × 104 in active infections (Abedi et al. 2015).
Most recipient children are HHV-6 seropositive prior to
SCT. Higher levels post-transplant of either HHV-6 or HHV-
7 antibodies, antigenemia, and DNA detection are more fre-
quent in the allogeneic than in autologous recipients. Patients
who have undergone total body irradiation (TBI) have faced
reactivation of both HHV-6 and HHV-7 more often than those
not irradiated (Imataki and Uemura 2015; Savolainen et al.
2005). Males are more frequently affected (Sakai et al. 2011;
Hirabayashi et al. 2013; Endo et al. 2014; Ongrádi et al. 2014).
For patients with active HHV-6 infections, a slower CD8+ T
cells recovery was observed until 6-months post-transplanta-
tion, and the overall probability of survival after allogeneic
HSCTwas diminished (Quintela et al. 2016). HHV-6 has been
linked to acute hemorrhagic encephalitis (AHE) in adults;
ANE is more frequent in childhood, although HHV-7-
induced AHE has been seen recently (Fay et al. 2015).
Roseolovirus-associated encephalitis is rare after SOT, but
recipients of heart, lung (Lautenschläger and Razonable
2012), or liver transplant (Dockrell et al. 1999; Singh and
Paterson 2000; Yoshikawa et al. 2002b) are at a slightly
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increased risk. An association has been documented between
a high HHV-6 level in the blood and PBMC, and CNS dys-
function and encephalitis (Ogata et al. 2006; Zerr et al. 2011).
HHV-6 was detected more frequently in the CSF of transplant
recipients with encephalitis than in those without encephalitis
(Zerr 2006). Warning signs for onset of encephalitis or en-
cephalopathy are hypercytokinemia, particularly high IL-6
levels in the early phase of SCT because of engraftment syn-
drome, and graft-versus-host disease (GVHD; Ogata et al.
2010). In allogeneic HSCT recipients, active HHV-6 infection
was significatly more often associated with CMV and or BK
virus but not EBV co-reactivations (Quintela et al. 2016). Risk
factors and clinical outcomes after HSCT differ between sin-
gle reactivations of HHV-6, CMV, or EBV (Drobyski et al.
1994; Jaskula et al. 2010).
Patients of any age with malignancies (Martikainen et al.
2013) and those who receive HSCTundergo combined chemo-
therapy regimens, biological therapy (e.g., anti-T cell antibod-
ies), and intracranial or total body irradiation (Drobyski et al.
1994; Imataki and Uemura 2015; Kawamura et al. 2013, 2012;
Ogata et al. 2010; Raspall-Chaure et al. 2013; Wittekindt et al.
2009; Zerr et al. 2011). These combinations frequently contain
drugs, such as anti-cancer agent histone deacetylase (HDAC)
inhibitors, that are able to activate HHV-6 and HHV-7 or other
viruses in vitro and in vivo, particularly in the CNS (Yao et al.
2008). Certain common pharmaceuticals, among them aliphat-
ic acid derivates, anticonvulsant, analgesic, antipyretic, anti-
emetic, anesthetic or immunosuppressant drugs, and antibiotics
can reactivate or enhance an already existing HHV-6 infection
in vitro. Similar in vivo associations have mainly been found in
the context of drug-induced hypersensitivity syndrome (DIHS)
or drug rash with eosinophilia and systemic symptoms
(DRESS). HDAC inhibitor trichostatin A, hydrocortisone,
and 12-O-tetradecanoyl-13-acetate (TPA) have all been shown
to reactivate ciHHV-6 in vitro (Arbuckle et al. 2010; Iwasaki
et al. 2014; Mardivirin et al. 2009, 2010; references in Pellett
et al. 2012) In an elderly man, glycocorticoid treatment elicited
HHV-6 encephalitis (Yajima et al. 2014), and anti-rheumatic
therapy in a patient suffering from HHV-7+CMV-associated
encephaloradiculomyelitis contained dexamethamethasone
(Ginanneschi et al. 2007). Immunosuppression is vital for
transplant recipients, and although it may be difficult to alter
treatment protocols, the use of these drugs should be carefully
considered in the context of an HHV-6 infection, restricted to a
minimum, and potential effects on the viruses should be mon-
itored (Arbuckle et al. 2010; Montoya et al. 2012; Pellett et al.
2012).
Diagnosis
Infection of the CNS is difficult to diagnose. There is no con-
sensus for testing a standard set of biomarkers in suspected
roseolovirus-associated encephalitis (Agut 2011; Gautheret-
Dejean et al. 2013).
Clinical manifestations and other relevant information
The patient’s history is mandatory in the assessment of
suspected encephalitis. Immunocompromised conditions
and use of recreational drugs or medications known to
affect the immune system or reactivate latent viruses have
to be declared (Steiner et al. 2010). Neurological compli-
cations wrongly attributed to routine childhood vaccina-
tion may in fact be due to coincident primary virus infec-
tion (Ward 2005; Yavarian et al. 2014). Exanthem
subitum, pityriasis rosea, skin rash, and fever with con-
comitant neurological symptoms suggest an association
between viruses and CNS disorders (Savolainen et al.
2005; Yao et al. 2010a). Additionally, behavioral, cogni-
tive, visual, and verbal memory functions including am-
nesia, delirium and disorientation, focal neurological
signs, seizures, and autonomous and hypothalamic distur-
bances reflect disruptions of brain functions (Steiner et al.
2010; Zerr et al. 2011). Other common symptoms report-
ed are hyponatremia, hemophagocytosis, nystagmus, and
dysesthesia. Differentiation between HHV-6 encephalitis
and Wernicke encephalopathy occurring in pediatric
HSCT recipients improves outcome (Sadighi et al.
2015). In cancer patients, neurologic symptoms usually
attributable to brain metastases should be evaluated to
exclude a non-oncological cause (Mordenti et al. 2013).
Laboratory procedures
Electroencephalography and neuroimaging
EEG and baseline quantitative EEG (QEEG) can show abnor-
malities prior to neuroimaging. Several abnormalities, espe-
cially in the temporal lobe, have been described in both acute
or reactivated HHV-6 and ciHHV-6-associated encephalitis,
including slow wave activity in primary HHV-6B or HHV-7
infection-associated encephalitis consistent with brain stem
involvement. EEG normalization parallels antiviral treatment
and clinical improvement (Al-Zubeidi et al. 2014; Iwasaki
et al. 2014; Montoya et al. 2012; Pohl-Koppe et al. 2001;
Venancio et al. 2014; Ward et al. 2002; Wittekindt et al.
2009; Yamamoto et al. 2015).
Characteristic neuroradiographic signs of HHV-6-
associated encephalitis or encephalopathy in both immuno-
competent and immunocompromised patients have been rec-
ognized using CT scanning (Al-Zubeidi et al. 2014; Kadwabe
et al. 2010; Yao et al. 2010a; Zerr, 2006), MRI (Al-Zubeidi
et al. 2014; Chapenko et al. 2016; Crawford et al. 2009;
Drobyski et al. 1994; Hirabayashi et al. 2013; Kawamura
et al. 2013), and FLAIR MRI (Kawamura et al. 2013, 2012;
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Maramattom 2015; Venancio et al. 2014; Yajima et al. 2014;
Yamamoto et al. 2015). Findings include diffuse high intensity
of the limbic system around bilateral, temporal, occipital, and
frontal areas (Imataki and Uemura 2015). Susceptibility
weighted imaging (Iwasaki et al. 2014) and acute phase 2-
deoxy-(F-18)-fluoro-D-glucose positron emission tomogra-
phy (FDG-PET; Hubele et al. 2012) are also used. Signs de-
velop gradually, but they are somewhat delayed as compared
to the clinical symptoms (Imataki and Uemura 2015). In
AESD, MRI shows no abnormalities during the first 2 days
of the illness, then reduced diffusion in the subcortical white
matter is generally observed at the time of the second episode
of seizures around the exanthematous period. These typical
findings are subsequently resolved and brain atrophy is ob-
served in the convalescent period (Kawamura et al. 2014).
HHV-6 encephalitis often involves the cortex, hippocampal,
and extrahippocampal structures involving the amygdala, en-
torhinal cortex, thalamus, hypothalamus and deep forebrain
structures, cerebellum, and brain stem. Edema, necrotization,
and sclerosis are frequently found ( Al-Zubeidi et al. 2014;
Corti et al. 2011; Drobyski et al. 1994; Kawamura et al. 2013;
Raspall-Chaure et al. 2013; Singh and Paterson 2000; Yao
et al. 2010a). In HHV-7 encephalomyelitis (Pohl-Koppe
et al. 2001; Ward et al. 2002) and simultaneous HHV-6+
HHV-7 (Holden and Vas 2007) reactivation-associated en-
cephalitis, CT and MRI have detected abnormalities in the
cortex, cerebellum, and hippocampus. Improvement parallels
antiviral therapy, but sequelae have detectable signs. In many
cases of encephalitis after primary HHV-7 infection, normal
neuroimaging was shown initially, but without proper treat-
ment, progressive brain atrophy could be detected (Schwartz
et al. 2014).
General studies on the blood and CSF
In HHV-6 encephalitis following HSCT, the CSF is usually
normal, except for elevated protein levels that occurs in some
but not all cases. Pleocytosis is rarely found (Corti et al. 2011;
de Ory et al. 2013; Iwasaki et al. 2014; Kawamura et al. 2013,
2012, 2014; Maramattom 2015; Wittekindt et al. 2009; Zerr
2006). Severe hyponatremia could be prodromal or concom-
itant with HHV-6-PALE (Kawaguchi et al. 2013; Raspall-
Chaure et al. 2013). In HHV-7 encephalitis, laboratory results
are extremely disparate. CSF examination might show normal
or elevated protein and glucose levels (Chan et al. 2002;
Imataki and Uemura 2015; Pohl-Koppe et al. 2001; Ward
et al. 2002), pleocytosis, predominantly lymphocytosis (Fay
et al. 2015; Schwartz et al. 2014). Coincident HHV-7 and
CMV reactivation has resulted in xanthochromia, pleiocytosis
with lymphocyte predominance, red blood cells (RBC), high
protein level, and oligoclonal IgG bands in CSF (Ginanneschi
et al. 2007). Measurements of cytokine and chemokine panels
in CSF and serum are progression markers (Kawabe et al.




Identifying clinically relevant HHV-6 or HHV-7 CNS infec-
tion is challenging due to their ubiquitous and persistent na-
ture (Agut 2011). Testing should distinguish between HHV-
6A and HHV-6B species in all cases (Hill et al. 2015a, b).
Detection of roseolovirus harbouring cells in CSF does not
prove etiology (Martikainen et al. 2013), but detection of rep-
licating HHV-6 or HHV-7 in the brain tissues would suggest it
(Yao et al. 2010a). Brain biopsy is not used in clinical practice,
but at autopsy, brain material should be obtained (Chapenko
et al. 2016). CSF and brain tissue samples rarely contain in-
fectious virus (Steiner et al. 2010). Cultivation has now been
replaced by the detection of specific nucleic acids (NA) by
PCR-based technologies on CSF, CSF cells, brain biopsy, tis-
sues, and blood PBMC. The demonstration of viral DNA in
blood or saliva alone must not be considered confirmatory in
the diagnosis of encephalitis (de Ory et al. 2013;
Lautenschläger and Razonable 2012; Pellett et al. 2012;
Raspall-Chaure et al. 2013; Zerr 2006). The highest viral yield
in CSF is generally obtained when the virus appears transient-
ly during the first week following onset of symptoms (de Ory
et al. 2013; Maramattom 2015; Ward 2005) and becomes al-
most undetectable as the antibody response commences in
week three and beyond (Ward 2005). Others have found that
the detectability of viruses in the blood increased after HSCT
and peaked at 21 days post-transplantation (Inazawa et al.
2015).
The presence of ciHHV-6 must also be considered in en-
cephalitis (Gautheret-Dejean et al. 2013; Zerr 2006; Zerr et al.
2011). CiHHV-6 can be confirmed in acutely ill patients by
performing PCR on hair follicle or fingernail samples where
active HHV-6 replication is not present (Endo et al. 2014; Hall
et al. 2010; Montoya et al. 2012; Ward et al. 2006), although
their plasma, serum, and blood always tests positive for HHV-
6 (Deconinck et al. 2013; Hall et al. 2010; Pellett et al. 2012;
Ward et al. 2006). Individuals with ciHHV-6 will invariably
show a high viral load in whole blood (>log 5.5; Pellett et al.
2012; Zerr et al. 2011). CSF HHV-6 levels will depend on the
level of cells, and can vary from high levels (104–
107 copies/ml; Gautheret-Dejean et al. 2013) to low levels in
ciHHV-6 patients with subacute illness (Montoya et al. 2012).
Serum and plasma levels vary significantly, depending on the
time between phlebotomy and centrifuge, and are of no value
in diagnosing or tracking ciHHV-6 patients (Pellett et al.
2012). Fluorescence in situ hybridization (FISH) of the pa-
tients’ cells can locate ciHHV-6 at chromosomes (Endo et al.
2014). It might occur that one of the HHV-6 species is
J. Neurovirol. (2017) 23:1–19 9
integrated and either a primary infection or reactivation of the
other HHV-6 species or HHV-7 elicits encephalitis. Active
infection in ciHHV-6 patients may improve with antivirals
(Endo et al. 2014; Kobayashi et al. 2011; Troy et al. 2008;
Wittekindt et al. 2009).
Nested PCR (nPCR) with higher sensitivity is commonly
used to detect roseoloviruses in CSF and brain materials
(Chan et al. 2002; Chapenko et al. 2016; Kawada et al.
2003; Li et al. 2014; Michael and Solomon 2012; Pohl-
Koppe et al. 2001; Yoshikawa et al. 2000). Multiplex PCR
(mPCR) assays simultaneously detect all herpesviruses in a
very small volume of CSF (Agut 2011; de Ory et al. 2013).
PCR-basedmethods are able to distinguish between HHV-6A,
HHV-6B, and HHV-7 (Chapenko et al. 2016; Hall et al. 2010;
Inazawa et al. 2015; Lautenschläger and Razonable 2012;
Tembo et al. 2015; Ward 2005; Zerr et al. 2011). Qualitative
mPCR for the most important encephalitis-inducing microbes
is employed as a first-line screening test and subsequently
real-time PCR is used for quantitative evaluation of the actual
microbe (Chapenko et al. 2016; de Oliveira et al. 2015;
Inazawa et al. 2015). The finding of HHV-6 DNA in acellular
samples is considered a sign of virus replication, but in whole
blood and PBMCs and in ciHHV-6 patients an active infection
is best proven by quantitating viral mRNA using reverse tran-
scriptase (RT) PCR (Agut 2011; Epstein et al. 2012; Miranda
et al. 2011; Ward 2005). Viral load measurements through
quantitative PCR (qPCR) before, during, and after onset of
encephalitis allow for a more comprehensive understanding
of the viral contribution to disease (Agut 2011; Deconinck
et al. 2013; Hill et al., 2015a, b; Laina et al. 2010; Ljungman
2002). Low-copy number (around 103/ml) of HHV-6 DNA in
CSF have been detected in many of the patients with HHV-6
encephalitis/encephalopathy during primary infection
(Kawamura et al. 2011, 2014), whereas CSF samples obtained
from post-transplant HHV-6 encephalitis patients have
contained significantly higher-copy number (Kawamura
et al. 2011). Real-time PCR can establish viral load in a shorter
amount of time (Kawada et al. 2003; Yavarian et al. 2014) and
constitutes a reliable diagnostic tool enabling timely initiation
of appropriate therapy and rapid assessment of the efficacy of
antiviral treatment strategies (Imataki and Uemura 2015;
Tomaszewska et al. 2014). The minimum detection level of
most real-time PCR is low, e.g., two copies per reaction, while
the threshold level for the development of HHV-6 encephalitis
seems to be around 104 copies/ml plasma (Kawabe et al. 2010;
Ogata et al. 2013b). Unfortunately, the absence of internation-
al standards for qPCR testing limits our ability to translate
these findings between laboratories. High viral loads, up to
2 × 106/ml, are shown throughout the brain, whereas high
levels of HHV-6 DNA in peripheral blood could rather be
associated with encephalopathy (Hirabayashi et al. 2013;
Yamamoto et al. 2014). Encephalitis and myelitis are associ-
ated with alteration of the BBB; the detection of viral DNA in
CSF by PCR might not discriminate between a CNS and a
systemic infection per se (Ginanneschi et al. 2007).
Comparison of real-time PCR of HHV-7 in the buffy coat
samples for latent infection (3.2 %) and plasma samples for
active infection (0.4 %) in 825 UCBT donors real-time PCR
for HHV-7 was used to test buffy coat samples for latent in-
fection (3.2 %) and plasma samples for active infection
(0.4 %) in 825 UCBT donors. These results suggests that this
is a useful test to identify donors with active infections so they
can be prevented from donating for some time (Abedi et al.
2015).
In autopsy specimens, histopathology has detected in-
creased brain microglia, perivascular lymphocyte cuffing,
and scattered focal hippocampal neuronal dropout, which
was nonpsecific, but consistent with viral encephalitis (Hill
et al. 2015a, b). Roseolovirus antigens can be demonstrated
in specific brain cells by immunofluorescent (IF) or
immunoperoxidase methods (Li et al. 2014; Savolainen et al.
2005), but these techniques seem unsatisfactory in CSF sam-
ples (Ward 2005). In encephalitis cases, high HHV-6 loads in
the hippocampus, basal ganglia, insular cortex, temporal lobe,
and cingular gyrus have been found. Additionally, astrogliosis
and neuronal loss in regions of the hippocampus paralleled
HHV-6 protein expression suggesting a productive infection
(Al-Zubeidi et al. 2014; Drobyski et al. 1994; Raspall-Chaure
et al. 2013; Yao et al. 2010a). In fatal HHV-6 encephalitis,
absence of viral inclusions has been reported (Al-Zubeidi
et al. 2014; Drobyski et al. 1994). The lack of a significantly
greater prevalence of HHV-6B in the hippocampus of patients
with UEP than in controls can be an important distinguishing
factor between encephalitis and encephalopathy, as a
significatly higher prevalence has been found in patients with
encephalitis (Chapenko et al. 2016). In HHV-7 encephalitis,
multiple foci of microscopic neuronal degeneration, hemor-
rhage, necrosis, and perivascular lymphocytic infiltration in
the brain stem have been shown (Chan et al. 2002; Fay et al.
2015). Using confocal laser-scanning microscopy for TLE
biopsies opened the door to simultaneously detecting
roseolovirus antigens along with altered cellular components
(Esposito et al. 2015).
Intrathecal antibody detection in the CSF of HHV-6 or
HHV-7 is strong evidence for etiology. Systemic serological
responses should not be considered for diagnosis. In a young
child, viral DNA is not always detectable (Epstein et al. 2012),
therefore, plasma DNA testing and serological analysis (with
fourfold increase in IgG titer or the presence of IgM antibod-
ies) are important in confirming a diagnosis. Combining CSF
PCR with serology is important to prove primary HHV-7 in-
fection when investigating CNS disease (Schwartz et al.
2014). Methods must distinguish primary antibody response
and pre-existing antibodies from reactivation, and primary
infection may be verified by the use of an IgG avidity test.
This test is required in immunocompromised patients as
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antibody titers may have decreased to the point of seronega-
tivity and the secondary antibody response may appear to be
that of a primary antibody response. An HHV-6A and HHV-
6B specific immunoblotting assay has been developed
(Higashimoto et al. 2012), and HHV-7 antibodies can be
shown by indirect IF, immunoblot, and immunoassays
(Ward 2005).
Differential diagnosis
In sporadic encephalitis, clinical symptoms and laboratory re-
sults can be very diverse and unusual. Therefore, it is necessary
to test for a variety of pathogens, including different herpesvi-
ruses, enteroviruses, influenzaviruses, parainfluenzaviruses, ad-
enoviruses, as well as chlamydophila, mycoplasma, toxoplas-
ma, and campylobacter species (de Oliveira et al. 2015;
Esposito et al., 2015; Fay et al. 2015; Hill et al., 2015a, b;
Inazawa et al. 2015; Maramattom 2015; Martikainen et al.
2013; Quintela et al., 2016; Schwartz et al. 2014; Venancio
et al. 2014; Ward et al. 2002; Yao et al. 2008, 2010b). Viral
cultures and PCR are commonly performed on CSF and brain
tissue, as well as throat and stool specimens (Chan et al. 2002;
Holden and Vas 2007). Multivirus real-time PCR (Yamamoto
et al. 2015) and DNA microarrays are increasingly used to
identify several microbes and their genotypes simultaneously
(Boriskin et al. 2004; Miranda et al. 2011; Steiner et al. 2010).
Along with HHV-6-associated encephalitis, concomitant acy-
clovir resistant HSV-1 and adenovirus esophagitis, rotavirus
gastroenteritis, and respiratory syncytial virus penumonia were
all identified in a child (Ernst et al. 2012). Antigen detection of
adenoviruses, HSV, VZV, parainfluenzaviruses (Steiner et al.
2010), and influenzaviruses from throat samples may provide
a possible etiology for encephalitis, but these methods are not
helpful in diagnosis using CSF samples (Kawada et al. 2003;
Steiner et al. 2010). Serum antibody tests can be helpful in
retrospective studies, if there is a fourfold rise in antibody titer,
but do not help for intial acute case diagnosis. Microbiological
tests are required occasionally for measles, mumps, and rubella
in countries without effective vaccination programs, as well as
arboviruses and zoonosis in epidemic areas (de Ory et al. 2013;
Steiner et al. 2010). The simultaneous presence of several anti-
bodies in the CSF suggests BBB damage. Different viruses
induce different histological types of encephalitis. The major
targets of roseoloviruses are the brain stem (midbrain, pons, and
medulla oblongata), limbic area (amygdala and hippocampus),
and the medial temporal lobe. Anatomical injuries corrrespond
to clinical symptoms. Damage to the brain stem affects con-
sciousness and results in cardiorespiratory failure, while dam-
age to the limbic area results in elevated body temperature,
diuretic hormonal abnormalities, ataxia and cognitive and
memory impairments (hippocampus and amygdala), and dam-
age to the temporal lobe contributes to speech difficulties. HSV,
VZV, CMV, and HIV can induce panencephalitis, and RNA
viruses elicit patchy-nodular types. ADEMmight follow febrile
illnesses or immunization (Hoshino et al. 2012; Steiner et al.
2010). In pediatric patients, tuberculous meningitis (Steiner
et al. 2010) and HSV-1, HSV-2, VZV, and CMV infection
(Ibrahim et al. 2005) must be excluded. In Japan, influenza
virus was shown to be the most common pathogen in cases
of encephalopathy, followed by HHV-6 and rotavirus
(Hoshino et al. 2012). In another study, HSV-1, VZV, and
enteroviruses were found as the most common etiological
agents (de Ory et al. 2013). ANE usually following
influenzavirus A or enterovirus infections tends to cause
bilateral, sometimes hemorrhagic, injury to the thalami. Its
familial form is associated with mutations in the nuclear
pore protein RANBP2 (refs in Fay et al. 2015). The risk for
HAdV-associated encephalitis has been recognised in chil-
dren with unrelated or cord blood HSCT, GVHD grades
III–IV, and lymphopenia. In contrast to HHV-6 and 7, strict
isolation is necessary to prevent horizontal transmission
from fecal or urine contamination (Matthes-Martin et al.
2012; Mynarek et al. 2013). These data show the impor-
tance of differential diagnosis in handling patients and
protecting the health care staff from acquiring nosocomial
infect ion. Occasional ly, bacter ia l superinfect ion
(Ljungman 2002) or infection of other organs associated
with underlying diseases have to be recognised and treated
(Holden and Vas, 2007; Venancio et al., 2014). Death of
the patient could be due to an intercurrent infecton (Imataki
and Uemura 2015). Clearly, there is a need for further
studies on the etiological role and interaction of unrelated
neurotropic viruses especially in cases with atypical clini-
cal manifestations (Chapenko et al. 2012a).
Antiviral therapy, prevention, and prognosis
Primary infection by roseoloviruses usually does not require
specific treament. It is not known whether antiviral treatment
of primary HHV-6B or HHV-7-associated febrile status
epilepticus would be beneficial (Epstein et al. 2012).
Clinical diagnosis of viral encephalitis before HHV-6 or
HHV-7 identification is usually suspected to be of HSV or
VZV origin. Acyclovir therapy is administered, but it has a
very limited effect or no effect at all against roseoloviruses
(Chan et al. 2002; Corti et al. 2011; Fay et al. 2015;
Ljungman 2002; Steiner et al. 2010; Tomaszewska et al.
2014; Venancio et al. 2014; Yamamoto et al. 2015; Zerr
et al. 2011). When reactivation of HHV-6 or HHV-7 is recog-
nized, anti-roseolovirus medication has to be initiated.
Foscarnet and ganciclovir (valganciclovir) are the first line
of defense, and cidofovir is the second (Deconinck et al.
2013; Mordenti et al. 2013; Prichard and Whitley 2014;
Venancio et al. 2014). In simultanous infections of HHV-6
and CMVor HHV-7 and CMV, ganciclovir was found to be
an effective treatment, but it has been determined in another
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case that the drug showed efficacy against CMVyet was un-
able to eliminate HHV-7 (Tomaszewska et al. 2014). Recent
treatment regimens recommended by different authors are
very similar. High-dose ganciclovir (18 mg/kg/day) or
60mg/kg foscarnet twice a day was empoyed for the treatment
of a CNS HHV-6 infection in an immunocompromised host
(Imataki and Uemura 2015). Generally, foscarnet 60 mg/kg
i.v. every 8 h or 90 mg/kg every 12 h (180 mg/kg/day), or
ganciclovir 5 mg/kg i.v. every 12 h are recommended for the
treatment of HHV-6 encephalitis after allogeneic stem cell
trasnplantation (Zerr 2015). Successful treatment protocol of
several HSCT recipients and other patients has been pub-
lished, but randomized placebo-controlled trials are lacking
(Holden and Vas 2007; Ljungman 2002; Pöhlmann et al.
2007; Sadighi et al. 2015). Antiviral therapy might last for
weeks to months and the general scheme follows that used
in case of CMV reactivation (Deconinck et al. 2013).
Clinical symptoms may vanish after several months of antivi-
ral therapy (Hirabayashi et al. 2013). Decrease of HHV-6
DNA in the CSF over time has been documented, but some
patients were left with lingering neurological compromise.
Epilepsy may develop subsequent to HHV-6 encephalitis,
which is refractory to multiple antiepileptic drugs (Al-
Zubeidi et al. 2014; Kawamura et al. 2013; Raspall-Chaure
et al. 2013). An HIV-1-infected patient with HHV-6-
associated encephalitis died despite cidofovir treatment
(Astriti et al. 2006). Therapeutic failure after ganciclovir
(Chan et al. 2002; Imataki and Uemura 2015) or foscarnet
(Holden and Vas 2007) application has been reported. Most
frequently, mutation of the phosphotransferase gene results in
ganciclovir resistance (Imataki and Uemura 2015). HHV-7 is
much less susceptible to ganciclovir treatment than HHV-6,
although full recovery from encephalitis has been described
(Miranda et al. 2011). In two children with HHV-6 encepha-
litis, seemingly healthy but carrying genetic mitochondrial
disorders, neurological symptoms did not cease following ini-
tiation of ganciclovir or foscarnet medication due to HHV-6B-
associated encephalitis (Al-Zubeidi et al. 2014). Mutants re-
sistant to foscarnet and cidofovir have already been described
(Prichard and Whitley 2014). In a Japanese study of allogene-
ic stem cell transplant patients, low-dose foscarnet did not
suppress HHV-6 reactivation sufficiently to prevent all cases
of HHV-6 encephalitis (Ogata et al. 2013a). Both foscarnet
and valganciclovir long-term therapy of ciHHV-6 patients
with CNS disturbances have been reported to be successful
resulting in a rapid fall in CSF and blood viral load and no
clinical sequele (Kobayashi et al. 2011; Montoya et al. 2012;
Pantry et al. 2013; Troy et al. 2008; Wittekindt et al. 2009),
although no clinical trials have been conducted. HHV-6B, but
not HHV-6A, was shown to be resistant to the antiviral effects
of IFN-alpha and -beta due to silencing of IFN-stimulated
genes (Jaworska et al. 2010). Clinical and virus free recovery
was achieved in a 11-year-old immunocompetent boy with
HHV-7-associated hemorrhagic brainstem encephalitis by ap-
plying IVIG, corticosteroids, and plasma exchange but no
antiviral medication (Fay et al. 2015).
Prophylactic ganciclovir can prevent HHV-6 reactivation
(Zerr 2006). Pre-emptive ganciclovir (Ogata et al. 2013a) or
foscarnet (Ishiyama et al. 2011) therapy was shown to be
successful in many, but not all, cases of HHV-6 or CMV
encephalitis in transplanted patients (Ishiyama et al. 2011;
Ljungman 2002). A recent study showed that high-dose
valacyclovir may be helpful as a prophylaxis against HHV-6
reactivation (Hill et al. 2015a, b). So far, no consensus has
been reached regarding appropiate preventive methods
(Ogata et al. 2013a). The recent guidelines from the
American Society of Transplantation do not recommend anti-
viral prophylaxis for HHV-6 infection, but for manifested dis-
ease, especially encephalitis, consideration of intravenous
ganciclovir and foscarnet are recommended (Lautenschläger
and Razonable 2012).
A lipophilic derivate of cidofovir, CMX001 (Brincidofovir)
can inhibit replication of both HHV-6A (strain GS) and HHV-
6B (strains Z29 and HST) in cell cultures (Bonnafous et al.
2013). In a phase 2 trial, it was found to prevent CMV disease
in HCT recipients (Marty et al. 2013), although a subsequent
phase III trial was suspended due to higher GVHD in the arm
with active drug compared to the control arm (Chimerix 2015).
Brincidofovir could prevent reactivation of a broad range of
viruses causing complications after HSCT including adenovirus
and could be used before the exact causative agent of enceph-
alitis is verified (Prichard andWhitley 2014). The development
of HHV-6 specific cytotoxic T cells for adoptive immunother-
apy has been encouraging. Several phase II and phase III clin-
ical trials with other drugs are in progress (see references in
Ogata et al. 2015; references in Prichard and Whitley 2014).
Antiviral drugs have serious side effects. Ganciclovir can cause
serious bone marrow suppression and foscarnet can cause renal
toxicity (Ward 2005; Hill et al. 2015a, b). As a curiosity, detri-
mental effect of ganciclovir on the residual POLG activity in
two immunocompetent children carrying mutations and HHV-
6B-associated encephalitis has been described (Al-Zubeidi
et al. 2014). Application of drugs with less toxicity are needed
for patients with severe underlying conditions (Papadopoulou
et al. 2014).
Conclusions
Roseoloviruses are important pathogens in immunocompetent
young people and immunocompromised individuals, espe-
cially in the transplantation setting, and cause serious and
lethal complications including CNS disorders. The scale of
the contribution of Roseolovirus infection to diverse neuro-
logical diseases has not been appreciated in the past (Steiner
et al. 2010), but such cases must now be fully investigated for
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these viruses. Individual case studies must be replaced by
properly selected cohorts with standardised diagnostic
procedures and adequate antiviral treatment. HHV-6B is more
prevalent than HHV-6A in cases of encephalitis and enceph-
alopathy in both immunocompetent and immunocopromised
individuals. Simultaneous primary betaherpesvirus infections,
and HHV-6 and/or CMV reactivation by HHV-7 have been
found in several cases of encephalitis and/or encephalopathy.
Hidden genetic disorders, e.g., defects of mitochodrial
enzymes might predispose small children to encephalitis or
encephalopathy during primary HHV-6B or HHV-7 infection.
Male gender, as well as young age for HHV-6B, but advanced
age for HHV-7 contribute to CNS disorders. In the transplan-
tation setting, certain HLA classs I alleles, advanced underly-
ing malignant diseases, but above all, UCBT, and repeated
SCT/HSCT are the most important risk factors for
roseolovirus-associated encephalitis. The clinical course and
sequelae seem to be more severe at any age in HHV-7-
associated CNS involvements than in HHV-6-associated
forms. Clinical symptoms, sophisticated neuroimaging proce-
dures and laboratory findings in the blood and CSF are very
diverse and vary by individual and differ in primary or
reactivated infections. Direct cell destruction due to virus
infection in the limbic system, brain stem, temporal lobe
combined with damages attributed to proinflammatory
cytokines elicit limbic encephalitis, and several other forms
of brain damages. For differential diagnostic purposes, mPCR
is recommended, while qPCR is used to monitor blood and
CNS copy number of the actual pathogen(s) during disease
course and to predict efficacy of treatment and outcome
(Gautheret-Dejean et al. 2013). Both exogenous and chromo-
somally integrated HHV-6A and HHV-6B have to be distin-
guished bymolecular methods. CiHHV-6 has been detected in
immunocompetent persons with both mild and severe CNS
disorders. Due to a lack of controlled trials, empirical therapy
of roseolovirus-associated encephalitis has been successful
when started very early in the disease course or in a preemp-
tive approach. Especially in ciHHV-6 patients, long-term
treatment is required (Pantry et al. 2013). Ganciclovir and
foscarnet are recommended as first-line agents, and cidofovir
is in the second line of defense because its ability to penetrate
the CNS has been poorly studied. Frequent delays due to
late diagnosis, inadequate (e.g., acyclovir), or no medication,
unavoidable treatment of serious underlying diseases with
drug combinations—that have roseolovirus-activating
potential—emergence of resistant betaherpesvirus mutants
in single or simultaneous infections (Agut 2011) or the
presence of co-pathogens (Steiner et al. 2010) maintain high
mortality rates. New drugs with wide antiviral activity (e.g.,
brincidofovir) and their combination with immunotherapy
(e.g., IVIG) or other types of therapy are required to combat
roseolovirus-associated CNS complications on a very carefully
balanced, individual basis.
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